Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, Eurosurveillance, vol.13, pp.4-6, 2004. ,
The epidemiology, natural history and prevention of hepatitis B : implications of HOV co-infection, Antivir Ther, vol.12, pp.3-13, 2007. ,
Immunology of hepatitis B virus and hepatitis C virus infection, Nature Reviews Immunology, vol.24, issue.3, pp.215-244, 2005. ,
DOI : 10.1172/JCI200318509
Hepatitis B and human immunodeficiency virus co-infection, World Journal of Gastroenterology, vol.20, issue.46, p.17360, 2014. ,
DOI : 10.3748/wjg.v20.i46.17360
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort, AIDS, vol.19, issue.6, pp.593-601, 2005. ,
DOI : 10.1097/01.aids.0000163936.99401.fe
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, vol.84, issue.4, pp.1306-1316, 1999. ,
DOI : 10.1002/hep.510290447
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) The Lancet, pp.1921-1927, 2002. ,
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study, Liver International, vol.56, issue.9, 2015. ,
DOI : 10.1111/liv.12777
Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalit?? 2010 survey, France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS), pp.230-239, 1995. ,
DOI : 10.1111/hiv.12204
Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Virus Infection. World Health Organization, 2015. ,
Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Ministère des Affaires sociales et de la santé. Prise en charge médicale des personnes vivant avec le VIH : rapport 2013: recommandations du groupe d'experts. La documentation française, 2013. ,
Hepatitis B Virus Infection, New England Journal of Medicine, vol.359, issue.14, pp.1486-500, 2008. ,
DOI : 10.1056/NEJMra0801644
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses, Gastroenterology, vol.139, issue.4, pp.1218-1247, 2010. ,
DOI : 10.1053/j.gastro.2010.06.042
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, vol.359, issue.23, pp.2442-55, 2008. ,
DOI : 10.1056/NEJMoa0802878
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B, Gastroenterology, vol.140, issue.1, pp.132-175, 2011. ,
DOI : 10.1053/j.gastro.2010.10.011
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, The Lancet, vol.381, issue.9865, pp.468-75, 2013. ,
DOI : 10.1016/S0140-6736(12)61425-1
Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis, PLoS ONE, vol.15, issue.7, p.68152, 2013. ,
DOI : 10.1371/journal.pone.0068152.s002
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial, The Lancet, vol.378, issue.9787, pp.238-284, 2011. ,
DOI : 10.1016/S0140-6736(11)60936-7
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir, Antivir Ther, vol.10, issue.6, p.727, 2005. ,
Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus, Clinical Infectious Diseases, vol.56, issue.9, pp.87-94, 2013. ,
DOI : 10.1093/cid/cit002
Direction Générale de la Santé, Ministère de la Santé et des solidarités Prise en charge médicale des personnes infectées par le VIH : rapport 2006 : recommandations du groupe d'experts. Flammarion médecine-sciences, 2006. ,
Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Ministère de la santé et des sports Prise en charge médicale des personnes infectées par le VIH : rapport 2010 : recommandations du groupe d'experts. La Documentation Française, 2010. ,
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, The Lancet, vol.385, issue.9987, 2015. ,
DOI : 10.1016/S0140-6736(15)60616-X
Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy, Antimicrobial Agents and Chemotherapy, vol.59, issue.6, pp.3563-3572, 2015. ,
DOI : 10.1128/AAC.00128-15
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection, Journal of Hepatology, vol.62, issue.3, pp.533-573, 2015. ,
DOI : 10.1016/j.jhep.2014.10.035
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?, AIDS, vol.24, issue.7, pp.1078-1087, 2010. ,
DOI : 10.1097/QAD.0b013e3283313f54
KDIGO Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease, Kidney Int Suppl, vol.31, 2012. ,
HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment, Nature Reviews Nephrology, vol.460, issue.3, pp.150-60, 2015. ,
DOI : 10.1038/nrneph.2015.9
Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004???2012, PLoS ONE, vol.22, issue.6, p.66223, 2004. ,
DOI : 10.1371/journal.pone.0066223.t003
URL : https://hal.archives-ouvertes.fr/hal-01101114
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France, HIV Medicine, vol.11, issue.5, pp.308-325, 2010. ,
DOI : 10.1111/j.1468-1293.2009.00780.x
La maladie rénale chronique Disponible sur http ,
Outcome and Prognosis Factors in HIV-Infected Hemodialysis Patients, Clinical Journal of the American Society of Nephrology, vol.1, issue.6, pp.1241-1248, 2006. ,
DOI : 10.2215/CJN.02211205
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons, AIDS, vol.28, issue.2, pp.187-99, 2014. ,
DOI : 10.1097/QAD.0000000000000042
Executive Summary: Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.59, issue.9, pp.1203-1210, 2014. ,
DOI : 10.1093/cid/ciu730
KDIGO Clinical Practice Guideline for Glomerulonephritis -Chapter 9: Infection-related glomerulonephritis, Kidney Int Suppl, vol.2, issue.2, pp.200-208, 2012. ,
HIV-associated kidney glomerular diseases: changes with time and HAART, Nephrology Dialysis Transplantation, vol.27, issue.6, pp.2349-55, 2012. ,
DOI : 10.1093/ndt/gfr676
URL : https://hal.archives-ouvertes.fr/inserm-00919151
Tubulointerstitial Nephropathies in HIV-Infected Patients over the Past 15 Years: A Clinico-Pathological Study, Clinical Journal of the American Society of Nephrology, vol.8, issue.6, pp.930-938, 2013. ,
DOI : 10.2215/CJN.10051012
URL : https://hal.archives-ouvertes.fr/inserm-00919109
Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999, Nephrology Dialysis Transplantation, vol.18, issue.9, pp.1824-1857, 1990. ,
DOI : 10.1093/ndt/gfg233
Diminished Impact of Ethnicity as a Risk Factor for Chronic Kidney Disease in the Current HIV Treatment Era, Journal of Infectious Diseases, vol.212, issue.2, pp.264-74, 2015. ,
DOI : 10.1093/infdis/jiv026
Factors associated with chronic renal failure in HIV-infected ambulatory patients, AIDS, vol.18, issue.16, pp.2171-2179, 2004. ,
DOI : 10.1097/00002030-200411050-00009
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study, PLOS Medicine, vol.15, issue.3, p.1001809, 2015. ,
DOI : 10.1371/journal.pmed.1001809.s001
Prevalence of renal abnormalities in chronic HBV infection: The HARPE study, Liver International, vol.32, issue.Suppl. 1, pp.148-55, 2015. ,
DOI : 10.1111/liv.12480
13-year nationwide cohort study of chronic kidney disease risk among treatment-na??ve patients with chronic hepatitis B in Taiwan, BMC Nephrology, vol.147, issue.A8, 2015. ,
DOI : 10.1053/j.gastro.2014.03.048
Treatment of hepatitis B in patients with chronic kidney disease, Kidney International, vol.84, issue.5, pp.880-885, 2013. ,
DOI : 10.1038/ki.2013.249
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B, Journal of Hepatology, vol.55, issue.6, pp.1235-1275, 2011. ,
DOI : 10.1016/j.jhep.2011.03.030
Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B, Alimentary Pharmacology & Therapeutics, vol.29, issue.9, pp.310-319, 2015. ,
DOI : 10.1111/apt.13036
Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults, PLoS ONE, vol.17, issue.4, p.40245, 2012. ,
DOI : 10.1371/journal.pone.0040245.t003
Chronic Hepatitis B Virus Coinfection Is Associated With Renal Impairment Among Zambian HIV-Infected Adults, Clinical Infectious Diseases, vol.59, issue.12, pp.1757-60, 2014. ,
DOI : 10.1093/cid/ciu734
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311179
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate, Journal of Viral Hepatitis, vol.24, issue.7, pp.650-657, 2013. ,
DOI : 10.1111/jvh.12088
Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?, Journal of the American Society of Nephrology, vol.24, issue.10, pp.1519-1546, 2013. ,
DOI : 10.1681/ASN.2012080857
Tenofovir Nephrotoxicity: 2011 Update, AIDS Research and Treatment, vol.26, issue.5, pp.1-11, 2011. ,
DOI : 10.1128/AAC.00068-10
URL : http://doi.org/10.1155/2011/354908
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities, Kidney International, vol.78, issue.11, pp.1171-1178, 2010. ,
DOI : 10.1038/ki.2010.318
modelling of differential HIV-1 progression and antiretroviral toxicity, Journal of Antimicrobial Chemotherapy, vol.70, issue.8, pp.2330-2336, 2015. ,
DOI : 10.1093/jac/dkv101
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations, AIDS, vol.24, issue.7, pp.1064-1070, 2010. ,
DOI : 10.1097/QAD.0b013e32833202e2
Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.43, issue.3, pp.278-83, 2006. ,
DOI : 10.1097/01.qai.0000243103.03265.2b
Renal Impairment in Patients Receiving a Tenofovir-cART Regimen, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.4, pp.375-80, 2013. ,
DOI : 10.1097/QAI.0b013e31827ce4ee
Gene Haplotypes and Tenofovir???Induced Proximal Tubulopathy, The Journal of Infectious Diseases, vol.194, issue.11, pp.1481-91, 2006. ,
DOI : 10.1086/508546
URL : http://jid.oxfordjournals.org/cgi/content/short/194/11/1481
The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients, Clinical Pharmacology & Therapeutics, vol.42, issue.2, pp.265-72, 2008. ,
DOI : 10.1038/sj.clpt.6100269
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202, Pharmacogenetics and Genomics, vol.25, issue.9, 2015. ,
DOI : 10.1097/FPC.0000000000000156
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function, Antimicrobial Agents and Chemotherapy, vol.57, issue.4, pp.1840-1843, 2013. ,
DOI : 10.1128/AAC.02434-12
Molecular assessment for the potential of renal drug interactions between tenofovir and HIV portease inhibitors, Antivir Ther, vol.12, pp.267-72, 2007. ,
SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen, Clinical Infectious Diseases, vol.56, issue.11, pp.1637-1682, 2013. ,
DOI : 10.1093/cid/cis1203
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, issue.11, pp.1667-78, 2010. ,
DOI : 10.1097/QAD.0b013e328339fe53
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients, Journal of Hepatology, vol.60, issue.4, pp.715-737, 2014. ,
DOI : 10.1016/j.jhep.2013.11.024
Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, vol.10, issue.8, pp.941-947, 2012. ,
DOI : 10.1016/j.cgh.2012.04.008
531 Tenofovir DF i i i and i i in Chronic Hepatitis B (CHB) patients with baseline decreased glomerular filtration rate, J Hepatol, vol.56, p.210, 2012. ,
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience, Clinical Microbiology and Infection, vol.22, issue.1, 2015. ,
DOI : 10.1016/j.cmi.2015.05.035
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir, Journal of Viral Hepatitis, vol.52, issue.1, pp.471-479, 2009. ,
DOI : 10.1111/j.1365-2893.2009.01084.x
Mesure et estimation du débit de filtration glomérulaire. Encyclopédie Médico-Chirurgiale, 2014. ,
Diagnostic de l'Insuffisance rénale chronique. Disponible sur http ,
Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons, American Journal of Kidney Diseases, vol.56, issue.5, pp.872-82, 2010. ,
DOI : 10.1053/j.ajkd.2010.05.019
Maladie Rénale Chronique de l'adulte -Guide du parcours de soin. Disponible sur http ,
Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure, Journal of Infectious Diseases, vol.210, issue.3, pp.363-73, 2014. ,
DOI : 10.1093/infdis/jiu107